Recently, Kechow Pharma, a company served by ZGC Development Group, was officially listed on the National Equities Exchange and Quotations (NEEQ)—the New Third Board. This marks that it has successfully entered into the capital market and is expected to further advance the clinical pipeline and secure additional operating funds.

Kechow Pharma, founded in 2014, is a new drug research and development company integrating drug discovery, clinical research and development, and sales. The company focuses on scientific innovation through independent research and development. All ongoing projects are original first-class new drugs with new compound structures.

Currently, the company's first product, the MEK inhibitor torlatinib (HL-085, Product Name: Keluoping ®) has been approved for marketing in China in March 2024. It is the world's first and only approved targeted drug for the indication of advanced melanoma with NRAS gene mutations, as well as the first home-made MEK inhibitor approved for marketing, filling the gap of therapeutic drugs for this indication.

ZGC Capital, a subsidiary of ZGC Development Group, invested in Kechow Pharma in November 2023. ZGC Capital has been committed to the goal of scientific and technological achievements transformation and industrialization by providing multi-dimensional comprehensive post-investment services for Kechow Pharma. In addition, ZGC Capital also assisted Kechow Pharma in conducting site investigations and selection for drug formulation factories in several districts and counties in Beijing, making early preparations for the future large-scale production of drugs.